Erasca
pivotal phase and phase trial designs capitalize on promising efficacy signals and support potential successful registration in multiple indications setae dor secondary | Erasca
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
21 of 41
Related slides by other companies
BioAtla
Investor Presentation
November 2022
phase study design with in refractory patients | BioAtla
MindMed
Investor Presentation
November 2024
for gad phase program overview | MindMed
Chimerix
Investor Presentation
March 2023
pivotal phase action trial design primary overall survival day | Chimerix
BioAtla
Investor Presentation
May 2023
phase study design with | BioAtla
Other recent decks by Erasca
See all presentations (4 decks)
Investor Presentation
November 2023
Investor Presentation
August 2023
IPO
July 2021
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights